Zag Bio was founded with a vision to develop more precise, potent, and impactful medicines for immune-mediated diseases. Zag Bio is working to discover and develop therapies targeted directly to the thymus, with the goal of generating central immune tolerance.  

 

Our technology platform is inspired by the work of co-founder Diane Mathis of Harvard Medical School, and operates across multiple therapeutic platforms, underpinned by a deep technical interrogation of thymus biology. In addition to Dr. Mathis, Zag Bio was co-founded by Alan Crane (Polaris Partners), Jo Viney (Seismic Therapeutics), and John Kulman (Zag Bio). Zag Bio is a stealth mode biotech company, poised for growth in line with our ambition to transform the treatment of immune-mediated diseases.